Full Boosted Fosamprenavir — Competitive Intelligence Brief

Full Boosted Fosamprenavir (Full Boosted Fosamprenavir) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HIV protease inhibitor. Area: Infectious Disease.

phase 3 HIV protease inhibitor HIV protease Infectious Disease Small molecule

Target snapshot

Full Boosted Fosamprenavir (Full Boosted Fosamprenavir) — GlaxoSmithKline. Fosamprenavir is a protease inhibitor that, when boosted with ritonavir, blocks HIV protease to prevent viral replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Full Boosted Fosamprenavir TARGET	Full Boosted Fosamprenavir	GlaxoSmithKline	phase 3	HIV protease inhibitor	HIV protease
Switch ritonavir-boosted PI	Switch ritonavir-boosted PI	Juan A. Arnaiz	marketed	Protease inhibitor (boosted)	HIV protease
DRV/r	DRV/r	Community Research Initiative of New England	marketed	Protease inhibitor (boosted)	HIV protease
Nelfinavir and Omeprazole	Nelfinavir and Omeprazole	Pfizer	marketed	HIV protease inhibitor + proton pump inhibitor combination	HIV protease (nelfinavir); H+/K+-ATPase proton pump (omeprazole)
Ritonavir (heat-stable)	Ritonavir (heat-stable)	Bristol-Myers Squibb	marketed	HIV protease inhibitor	HIV protease
Telzir®	Telzir®	ViiV Healthcare	marketed	HIV protease inhibitor	HIV protease
ZDV+3TC+LPV/r	ZDV+3TC+LPV/r	International Maternal Pediatric Adolescent AIDS Clinical Trials Group	marketed	Antiretroviral combination therapy (NRTI + PI)	HIV reverse transcriptase; HIV protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HIV protease inhibitor class)

1. Bristol-Myers Squibb · 5 drugs in this class
2. ViiV Healthcare · 3 drugs in this class
3. GlaxoSmithKline · 2 drugs in this class
4. Drugs for Neglected Diseases · 2 drugs in this class
5. Germans Trias i Pujol Hospital · 2 drugs in this class
6. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
7. DualityBio Inc. · 1 drug in this class
8. French National Agency for Research on AIDS and Viral Hepatitis · 1 drug in this class
9. Far East Bio-Tec Co., Ltd · 1 drug in this class
10. Community Research Initiative of New England · 1 drug in this class